InnoPharmax Inc. (TPEX:4172)
Taiwan
· Delayed Price · Currency is TWD 14.65
-0.20 (-1.35%)
Apr 29, 2026, 1:53 PM CST
InnoPharmax Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 97.28 | 166.73 | 39.36 | 40.53 | 90.51 | Upgrade
|
| Short-Term Investments | 49 | 114.5 | 100.3 | 55.85 | 96.76 | Upgrade
|
| Cash & Short-Term Investments | 146.28 | 281.23 | 139.66 | 96.37 | 187.26 | Upgrade
|
| Cash Growth | -47.98% | 101.37% | 44.91% | -48.54% | -22.58% | Upgrade
|
| Accounts Receivable | 1.83 | 4.53 | 6.96 | - | - | Upgrade
|
| Other Receivables | 0.89 | 0.47 | 0.82 | 0.57 | 4.03 | Upgrade
|
| Receivables | 2.72 | 5 | 7.78 | 0.57 | 4.03 | Upgrade
|
| Inventory | 15.12 | 18.34 | 25.53 | 30.5 | 16.12 | Upgrade
|
| Prepaid Expenses | 2.8 | 2.46 | 3.38 | 1.1 | 1.92 | Upgrade
|
| Other Current Assets | 8.58 | 13.26 | 12.65 | 8.2 | - | Upgrade
|
| Total Current Assets | 175.51 | 320.29 | 188.99 | 136.74 | 209.33 | Upgrade
|
| Property, Plant & Equipment | 3.42 | 8.59 | 13.77 | 19.57 | 13.77 | Upgrade
|
| Long-Term Investments | 251.32 | 261.21 | 269.14 | 278.43 | 283.97 | Upgrade
|
| Other Intangible Assets | 5.27 | 6.22 | 6.72 | 8.85 | 9.75 | Upgrade
|
| Long-Term Accounts Receivable | - | - | 6.09 | 6.09 | 6.09 | Upgrade
|
| Long-Term Deferred Tax Assets | 15.89 | 19.4 | 21.72 | 21.72 | 21.72 | Upgrade
|
| Other Long-Term Assets | 17.58 | 17.35 | 17.75 | 17.92 | 11.53 | Upgrade
|
| Total Assets | 468.98 | 633.06 | 524.2 | 489.31 | 556.16 | Upgrade
|
| Accounts Payable | 9.57 | 2.4 | 6.7 | 0.84 | 0.84 | Upgrade
|
| Accrued Expenses | 24.07 | 8.57 | 0 | 0.23 | 0.04 | Upgrade
|
| Short-Term Debt | 10 | 10 | 11.5 | 23.27 | - | Upgrade
|
| Current Portion of Leases | 0.82 | 4.57 | 4.48 | 4.42 | 4.5 | Upgrade
|
| Current Unearned Revenue | 3.64 | 2.44 | 0.18 | 0.18 | 0.18 | Upgrade
|
| Other Current Liabilities | 1.71 | 1.41 | 11.09 | 10.19 | 8.66 | Upgrade
|
| Total Current Liabilities | 49.81 | 29.4 | 33.95 | 39.13 | 14.22 | Upgrade
|
| Long-Term Leases | - | 0.82 | 5.39 | 9.86 | 1.08 | Upgrade
|
| Other Long-Term Liabilities | - | - | 9.32 | 9.32 | 9.32 | Upgrade
|
| Total Liabilities | 49.81 | 30.22 | 48.65 | 58.31 | 24.61 | Upgrade
|
| Common Stock | 1,076 | 1,076 | 949.97 | 868.36 | 867.19 | Upgrade
|
| Additional Paid-In Capital | 100.43 | 100.43 | 34.17 | 0.77 | 52.86 | Upgrade
|
| Retained Earnings | -757.01 | -572.96 | -507.84 | -437.48 | -386.89 | Upgrade
|
| Comprehensive Income & Other | - | -0.44 | -0.75 | -0.66 | -1.61 | Upgrade
|
| Shareholders' Equity | 419.18 | 602.85 | 475.55 | 431 | 531.54 | Upgrade
|
| Total Liabilities & Equity | 468.98 | 633.06 | 524.2 | 489.31 | 556.16 | Upgrade
|
| Total Debt | 10.82 | 15.39 | 21.36 | 37.56 | 5.57 | Upgrade
|
| Net Cash (Debt) | 135.46 | 265.84 | 118.29 | 58.82 | 181.69 | Upgrade
|
| Net Cash Growth | -49.04% | 124.73% | 101.12% | -67.63% | -14.29% | Upgrade
|
| Net Cash Per Share | 1.26 | 2.73 | 1.28 | 0.68 | 2.10 | Upgrade
|
| Filing Date Shares Outstanding | 107.58 | 107.58 | 95 | 86.84 | 86.72 | Upgrade
|
| Total Common Shares Outstanding | 107.58 | 107.58 | 95 | 86.84 | 86.72 | Upgrade
|
| Working Capital | 125.7 | 290.89 | 155.05 | 97.61 | 195.11 | Upgrade
|
| Book Value Per Share | 3.90 | 5.60 | 5.01 | 4.96 | 6.13 | Upgrade
|
| Tangible Book Value | 413.91 | 596.62 | 468.82 | 422.15 | 521.8 | Upgrade
|
| Tangible Book Value Per Share | 3.85 | 5.55 | 4.94 | 4.86 | 6.02 | Upgrade
|
| Machinery | 35.94 | 35.67 | 35.14 | 34.74 | 36.97 | Upgrade
|
| Leasehold Improvements | 0.66 | 0.66 | 0.66 | 0.66 | 0.66 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.